Overview
Ipamorelin is a ghrelin-receptor agonist investigated in humans for gastrointestinal recovery after bowel surgery.[1] The evidence discussed here includes early human pharmacology work and a later hospital-based trial, with distinct populations and outcomes.[1][2] Neither setting directly establishes the sleep or training-recovery claims made for subcutaneous ipamorelin or combinations with CJC-1295.[1][2] This guide explains what those studies measured, how the route and clinical setting limit interpretation, and why a growth-hormone response should be considered separately from demonstrated improvement in symptoms, physical function, or long-term safety.
Benefits
The human studies reviewed here do not establish that ipamorelin improves sleep quality or training recovery, either alone or combined with CJC-1295.[1][2] Early human work examined its pharmacokinetics and growth-hormone response, while a later randomized trial studied intravenous ipamorelin after bowel surgery.[1][2] Neither setting directly tests the sleep or recovery claims made for subcutaneous combinations.[1][2] Evidence that a compound stimulates growth hormone is not interchangeable with evidence of better sleep architecture, physical function, or recovery time.[1][2] A combination also requires its own evaluation rather than assuming that separate hormone effects add up to clinical benefit.[1][2]
Safety
FDA flags serious events, including death, reported during intravenous ipamorelin research for gastric motility; this wording does not establish that ipamorelin caused every event.[3] The agency also says evidence is insufficient to characterize harm through certain other injectable routes.[3] The published postoperative trial studied hospitalized surgical patients, so its safety observations cannot establish the safety of long-term use in healthy people.[1]
Contraindications
The early pharmacology study enrolled healthy men, while the postoperative trial enrolled adults undergoing bowel resection.[1][2] Those selected populations do not establish a validated contraindication list or demonstrate suitability during pregnancy or childhood; study eligibility should not be presented as a clinical prescribing rule.[1][2] Eligibility criteria show whom researchers chose to study; they are not a complete assessment of who can safely receive a product. Any conclusion about suitability therefore needs the exact formulation, the person’s health history, and evidence that actually addresses the relevant circumstances.
Interactions
The pharmacology study measured ipamorelin and GH after infusion; it did not test coadministration with CJC-1295.[2] Our interpretation is that these hormone measurements cannot establish combination safety, added benefit or dose adjustments.[2] To evaluate an interaction, the evidence needs to address the substances together and describe the outcome being monitored. Separate studies cannot establish the combined effect, and an unanswered interaction question should remain an uncertainty rather than becoming reassurance.
Forms & dosing
The cited pharmacology study and postoperative trial used intravenous infusion, with the surgical trial administering treatment in hospital for up to seven days or until discharge.[1][2] Those study regimens do not validate a subcutaneous home-use schedule or a mixture containing other peptides.[1][2] The amount administered is only one part of an intervention: formulation, route, frequency, treatment duration, and monitoring also define what was tested. Keeping those details attached to a result prevents a research schedule from being presented as a validated regimen for a different use.
Results & stopping
In healthy men receiving intravenous ipamorelin, its terminal half-life was about two hours and GH rose transiently before declining.[2] In the postoperative randomized trial, ipamorelin did not significantly improve the primary or secondary efficacy measures; neither study establishes lasting recovery benefits after stopping.[1][2] Time to a measured response and persistence after treatment ends are separate questions. A meaningful interpretation needs to specify the outcome, when it was assessed, and whether follow-up actually continued after treatment stopped, rather than infer lasting benefit from an early response.
Product quality
FDA identifies potential immune reactions related to aggregation or peptide impurities, and notes that ipamorelin’s unnatural amino acids complicate characterization.[3] For compounded products generally, FDA also warns that contamination or excessive active ingredient can cause serious injury; a product’s availability does not establish its quality.[4] A useful quality assessment needs to connect the tested sample to the actual product and explain what the test can establish. Evidence about identity or composition should remain distinct from evidence that the finished product is effective, suitable for a particular route, or clinically safe.
Status
At the October 3, 2026 check, ipamorelin acetate remained in FDA’s 503B Category 2 and also appeared among withdrawn nominations.[3] These compounding classifications do not constitute approval: compounded drugs are not FDA-approved or reviewed by the agency before marketing for safety, effectiveness and quality.[4] Regulatory status needs to be read for the exact substance, finished product, indication, and jurisdiction being discussed. A research publication, a supplier listing, and a regulatory decision answer different questions, so none should be used as a substitute for the others.
Evidence
These assessments describe confidence in a specific outcome for the population and formulation actually studied. Select an outcome or source count to inspect the supporting sources, methods, and limitations before applying a finding to a broader claim. Research on an individual ingredient is kept separate from evidence about a complete stack, and laboratory findings are distinguished from clinical outcomes. An unassessed question remains unresolved; it should not be read as evidence of either effectiveness or ineffectiveness. How we grade evidence.
| Outcome, finding and study design | Evidence certainty | Sources |
|---|---|---|
| Human researchHuman pharmacology and unrelated clinical-indication studies.[1][2] The human studies reviewed here do not establish that ipamorelin improves sleep quality or training recovery, either alone or combined with CJC-1295.[1][2] Early human work examined its pharmacokinetics and growth-hormone response, while a later randomized trial studied intravenous ipamorelin after bowel surgery.[1][2] Neither setting directly tests the sleep or recovery claims made for subcutaneous combinations.[1][2] Main limitation: No matched clinical-outcome trial identified for these claims.[1][2] |
Research Feed
Studies
Open a study to read its findings and limits, then explore the source passages and PDF details. Numbered citations link to References below.
Attenuation of Visceral and Somatic Nociception by Ghrelin Mimetics
Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus
Growth Hormone (GH) Hypersecretion and GH Receptor Resistance in Streptozotocin Diabetic Mice in Response to a GH Secretagogue
FAQs
Does ipamorelin, alone or with CJC-1295, improve sleep and recovery?
The human studies reviewed here do not establish that ipamorelin improves sleep quality or training recovery, either alone or combined with CJC-1295.[1][2] Early human work examined its pharmacokinetics and growth-hormone response, while a later randomized trial studied intravenous ipamorelin after bowel surgery.[1][2] Neither setting directly tests the sleep or recovery claims made for subcutaneous combinations.[1][2] Evidence that a compound stimulates growth hormone is not interchangeable with evidence of better sleep architecture, physical function, or recovery time.[1][2] A combination also requires its own evaluation rather than assuming that separate hormone effects add up to clinical benefit.[1][2]
Update History
Evidence and review status
- Recorded source check
- Subsequent substantive evidence update
- No later update is recorded for Ipamorelin.
- Independent clinical review
- Pending; this selected-source guide is AI-assisted.
A source-check date is not an exhaustive literature-search cutoff or an independent approval. Adding a paper to the catalogue does not mean its findings have been incorporated into an outcome assessment.
Read the editorial methodReferences
6 sources
- Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients (2014)Primary researchReview status · PendingSave study
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers (1999)Primary researchReview status · PendingSave study
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Accessed 2026-10-03)Regulatory guidanceSave study
- Understanding the Risks of Compounded Drugs (Accessed 2026-10-03)Regulatory guidanceSave study
- CJC 1295 no Dac with Ipamorelin for sleep
- Do GH Secretagogues Affect Blood Sugar?
Selected public discussions help us choose questions. They are not clinical evidence. Explore discussions
